Skip to main content
SpringerLink
Log in

Postmenopausal Hormone Therapy

Impact on Menopause-Related Symptoms, Chronic Disease and Quality of Life

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Quality of life in climacteric and postmenopausal women is often compromised. This overview addresses the many factors that may interfere with health and well-being in such women. Hormonal changes during the menopausal transition, finally resulting in estrogen deficiency, play a pivotal role in the incidence of climacteric symptoms and also in the development of chronic diseases. Such symptoms and diseases can contribute to impaired quality of life in climacteric and postmenopausal women. Postmenopausal hormone therapy (PHT) is the treatment of first choice to alleviate symptoms of estrogen deficiency. Besides effectively relieving climacteric symptoms and complaints, PHT can also protect against some chronic diseases, such as osteoporosis and colorectal cancer.

Presently, available PHTs vary widely in type, estrogen and progestogen dosage, and route and duration of administration. Furthermore, the number of alternatives to treat climacteric symptoms, and/or to prevent chronic diseases, has increased. Therefore, doctors involved in the care of climacteric women in the 21st century are much more able to meet the specific needs of individual patients and improve health and quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Fig. 1
Fig. 2
Table V
Table VI

Similar content being viewed by others

References

  1. Kenemans P, Barentsen R, van de Weijer PHM. Practical HRT. 2nd rev. ed. Zeist, The Netherlands: Medical Forum, 1996

    Google Scholar 

  2. Eskin BA. The menopause: comprehensive management. 4th ed. New York: Parthenon Publishing Group, 2000

    Google Scholar 

  3. Greene JG, Cooke DJ. Life stress and symptoms at the climacterium. Br J Psychiatry 1980; 136: 486–91

    Article  PubMed  CAS  Google Scholar 

  4. Glazer G, Zeller R, Delumba L, et al. The Ohio Midlife Women’s Study. Health Care Women Int 2002; 23: 612–30

    Article  PubMed  Google Scholar 

  5. Bosworth HB, Bastian LA, Rimer BK, et al. Coping styles and personality domains related to menopausal stress. Womens Health Issues 2003; 13: 32–8

    Article  PubMed  Google Scholar 

  6. Sandier B, Kase NG. Normal and abnormal menstruation. In: Kase NG, Weingold AB, Gershenson DM, editors. Principles and practise of clinical gynecology. 2nd ed. New York: Churchill Livingstone, 1990: 151–62

    Google Scholar 

  7. Cowan BD, Morrison JC. Management of abnormal genital bleeding in girls and women. N Engl J Med 1991; 324: 1710–5

    Article  PubMed  CAS  Google Scholar 

  8. Samsioe G. Bleeding problems in middle aged women. Maturitas 2002; 43 Suppl. 1: S27–33

    Article  PubMed  Google Scholar 

  9. Oldenhave A, Netelenbos C. Pathogenesis of climacteric complaints: ready for the change? Lancet 1994; 343: 649–53

    Article  PubMed  CAS  Google Scholar 

  10. Oldenhave A, Jaszmann LJ, Haspels AA, et al. Impact of climacteric on well-being: a survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993; 168: 772–80

    PubMed  CAS  Google Scholar 

  11. Greene JG. Constructing a standard climacteric scale. Maturitas 1998; 29: 25–31

    Article  PubMed  CAS  Google Scholar 

  12. Schneider HP. The quality of life in the post-menopausal woman. Best Pract Res Clin Obstet Gynaecol 2002; 16: 395–409

    Article  PubMed  Google Scholar 

  13. Brincat M, Moniz CJ, Studd JW, et al. Long-term effects of the menopause and sex hormones on skin thickness. Br J Obstet Gynaecol 1985; 92: 256–9

    Article  PubMed  CAS  Google Scholar 

  14. Cummings SR, Kelsey JL, Nevitt MC, et al. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985; 7: 178–208

    PubMed  CAS  Google Scholar 

  15. Kanis JA, McCloskey EV. Epidemiology of vertebral osteoporosis. Bone 1992; 13 Suppl. 12: S1–10

    PubMed  Google Scholar 

  16. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women: Study of Osteoporotic Fractures Research Group. N Engl J Med 1998; 339: 733–8

    Article  PubMed  CAS  Google Scholar 

  17. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997; 103: 12S–7S

    Article  PubMed  CAS  Google Scholar 

  18. Browner WS, Pressman AR, Nevitt MC, et al. Mortality following fractures in older women: the study of osteoporotic fractures. Arch Intern Med 1996; 156: 1521–5

    Article  PubMed  CAS  Google Scholar 

  19. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 1993; 329: 247–56

    Article  PubMed  CAS  Google Scholar 

  20. Thorn TJ, Kannel WB, Siberhshatz H, et al. Incidence, prevalence, and mortality of cardiovascular disease in the United States. In: Alexander RW, Schlant RC, Fuster V, editors. New York: McGraw-Hill, 1997: 3–17

  21. Gordon T, Kannel WB, Hortland MC, et al. Menopause and coronary heart disease. Ann Intern Med 1978; 89: 157–61

    PubMed  CAS  Google Scholar 

  22. Smolders RGV, van der Mooren MJ. New emerging risk factors for cardiovascular disease. J Br Menopause Soc 2000; 6: 27–33

    Google Scholar 

  23. Lloyd-Jones DM, Larson MG, Beiser A, et al. Lifetime risk of developing coronary heart disease. Lancet 1999; 353: 89–92

    Article  PubMed  CAS  Google Scholar 

  24. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA 2002; 288: 1388–95

    Article  PubMed  Google Scholar 

  25. Messinger-Rapport BJ, Sprecher D. Prevention of cardiovascular diseases: coronary artery disease, congestive heart failure, and stroke. Clin Geriatr Med 2002; 18: 463–83

    Article  PubMed  Google Scholar 

  26. Rowe JW, Kahn RL. Successful ageing. Gerontologist 1997; 37: 433–40

    Article  PubMed  CAS  Google Scholar 

  27. Harvey PD, Dahlman KL. Neuropsychological evaluation of dementia. In: Chalev A, editor. Neuropsychological assessment of neuropsychological disorders. Washington, DC: American Psychiatric Press, 1999: 329–77

    Google Scholar 

  28. Barrett-Connor E, Kritz-Silverstein D. Gender differences in cognitive function with age: the Rancho Bernardo Study. J Am Geriatr Soc 1999; 47: 159–64

    PubMed  CAS  Google Scholar 

  29. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988; 13: 345–57

    Article  PubMed  CAS  Google Scholar 

  30. Sherwin BB, Philips S. Estrogen and cognitive functioning in surgically menopausal women. Ann N Y Acad Sci 1990; 592: 474–5

    Article  Google Scholar 

  31. Philips S, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992; 17: 485–95

    Article  Google Scholar 

  32. Jacobs DM, Tang MX, Stern Y, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology 1998; 50: 368–73

    Article  PubMed  CAS  Google Scholar 

  33. Singer DE, Nathan DM, Anderson KM, et al. Association of HBA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992; 41: 202–8

    Article  PubMed  CAS  Google Scholar 

  34. Hubert HB, Feinleib M, McNamara P, et al. Obesity as an independent risk factor for cardiovascular disease: a 26 year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 768–77

    Article  Google Scholar 

  35. National Task Force on the Prevention and Treatment of Obesity. Long term pharmacotherapy in the management of obesity. JAMA 1996; 276: 1907–15

    Article  Google Scholar 

  36. Brincat M, Moniz CF, Kabalan S, et al. Decline in skin collagen content and metacarpal index after the menopause and its prevention with sex hormone replacement. Br J Obstet Gynaecol 1987; 94: 126–9

    Article  PubMed  CAS  Google Scholar 

  37. Brincat MP. Hormone replacement therapy and the skin. Maturitas 2000; 35: 107–17

    Article  PubMed  CAS  Google Scholar 

  38. Boiger EO. Commencement and maintenance compliance of patients on hormone replacement therapy (HRT) following bilateral oophorectomy. J Obstet Gynaecol 2001; 21: 173–4

    Article  Google Scholar 

  39. Campbell S, Whitehead M. Oestrogen therapy and the postmenopausal syndrome. Clin Obstet Gynecol 1977; 4: 31–47

    CAS  Google Scholar 

  40. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Available in The Coch-rane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2001: CD002978

    Google Scholar 

  41. Kenemans P, van Unnik GA, Mijatovic V, et al. Perspectives in hormone replacement therapy. Maturitas 2001; 38 Suppl. 1: S41–8

    Article  PubMed  CAS  Google Scholar 

  42. Genazzani AR, Gambacciani M. HRT in the third millennium. Maturitas 2001 Jun 15; 38 Suppl. 1: S49–55

    Article  PubMed  Google Scholar 

  43. Cardozo L, Robinson D. Special considerations in premenopausal and postmenopausal women with symptoms of over-active bladder. Urology 2002; 60 (5 Suppl. 1): 64–71

    Article  PubMed  Google Scholar 

  44. Rice VM. Optimizing the dose of hormone replacement therapy. Int J Fertil Womens Med 2002; 47: 205–10

    PubMed  Google Scholar 

  45. Ulrich LG, Barlow DH, Sturdee DW, et al. Quality of life and patient preference for sequential versus continuous combined HRT: the UK Kliofem multicenter study experience. UK Continuous Combined HRT Study Investigators. Int J Gynaecol Obstet 1997; 59 Suppl. 1: S11–7

    CAS  Google Scholar 

  46. Fitzpatrick LA, Pace C, Wiita B. Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. J Womens Health Gend Based Med 2000; 9: 381–7

    Article  PubMed  CAS  Google Scholar 

  47. Wu MH, Pan HA, Wang ST, et al. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric 2001; 4: 314–9

    PubMed  CAS  Google Scholar 

  48. Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas 2003; 44: 157–63

    Article  PubMed  CAS  Google Scholar 

  49. Hays J, Ockene JK, Branner R, et al., for the Women’s Health Initiative Investigators. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348: 1839–54

    Article  PubMed  CAS  Google Scholar 

  50. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285: 2909–10

    Article  Google Scholar 

  51. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33

    Article  Google Scholar 

  52. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17β-estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis 1986; 6: 57–63

    Article  Google Scholar 

  53. Haarbo J, Leth-Espersen P, Stender S,et al. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J Clin Invest 1991; 87: 1274–9

    Article  PubMed  CAS  Google Scholar 

  54. Stevenson JC, Crook D, Godsland IF, et al. Hormone replacement therapy and the cardiovascular system: nonlipid effects. Drugs 1994; 47 Suppl. 2: 35–41

    Article  PubMed  Google Scholar 

  55. Williams JK, Anthony MS, Honore EK, et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 1995; 15: 827–36

    Article  PubMed  CAS  Google Scholar 

  56. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199–208

    Article  Google Scholar 

  57. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–75

    Article  PubMed  CAS  Google Scholar 

  58. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55–72

    Article  PubMed  CAS  Google Scholar 

  59. Grodstein F, Stampfer MJ. Estrogen for women at varying risk of coronary disease. Maturitas 1998; 30: 19–26

    Article  PubMed  CAS  Google Scholar 

  60. Grodstein F, Manson JE, Colditz GA, et al. A prospective observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933–41

    PubMed  CAS  Google Scholar 

  61. Mijatovic V, van der Mooren MJ. Menopause, oestrogens, SERM’s and cardiovascular health in women. Eur J Obstet Gynecol Reprod Biol 2000; 93: 5–7

    Article  PubMed  CAS  Google Scholar 

  62. Van Baal WM, Kooistra T, Stehouwer CD. Cardiovascular disease risk and hormone replacement therapy (HRT): a review based on randomised, controlled studies in postmenopausal women. Curr Med Chem 2000; 7: 499–517

    Article  PubMed  Google Scholar 

  63. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–13

    Article  PubMed  CAS  Google Scholar 

  64. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522–9

    Article  PubMed  CAS  Google Scholar 

  65. Angerer P, Stork S, Kothny W, et al. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomised, controlled trial. Arterioscler Thromb Vasc Biol 2001; 21: 262–8

    Article  PubMed  CAS  Google Scholar 

  66. Hulley S, Furberg C, Barret-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002; 288: 58–66

    Article  PubMed  CAS  Google Scholar 

  67. Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study. Br J Obstet Gynaecol 2002; 109: 1056–62

    Article  CAS  Google Scholar 

  68. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. WHI Investigators: effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 2003; 289: 2673–84

    Article  PubMed  CAS  Google Scholar 

  69. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA 2002; 288: 366–8

    Article  PubMed  Google Scholar 

  70. Clarckson TB. The new conundrum: do estrogens have any cardiovascular benefits? Int J Fertil Womens Med 2002; 47: 61–8

    Google Scholar 

  71. Van der Mooren MJ, Kenemans P. Postmenopausal hormone replacement therapy in the light of the Women’s Health Initiative Trial. Eur J Obstet Gynecol Reprod Biol 2003; 107: 123–4

    Article  PubMed  Google Scholar 

  72. Genazzani AR, Gambacciani M, van der Mooren MJ, et al. Critical comments. Maturitas 2003; 44: 11–8

    Article  PubMed  Google Scholar 

  73. Toran-Allerand CD, Miranda RC, Bentham WD, et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A 1992; 89: 4668–72

    Article  PubMed  CAS  Google Scholar 

  74. Sohrabji F, Miranda RC, Toran-Allerand CD. Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci 1994; 14: 459–71

    PubMed  CAS  Google Scholar 

  75. Shumaker SA, Legault C, Thal L, et al., for the WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2651–62

    Article  PubMed  CAS  Google Scholar 

  76. Rapp SR, Espeland MA, Shumaker SA, et al., for the WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2663–72

    CAS  Google Scholar 

  77. Zandi PP, Breitner JC. Estrogen replacement and risk of Alzheimer disease. JAMA 2003; 289: 1100–2

    Article  Google Scholar 

  78. Spencer CP, Godsland IF, Cooper AJ, et al. Effects of oral and transdermal 17β-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism 2000; 49: 742–7

    Article  PubMed  CAS  Google Scholar 

  79. O’Sullivan AJ, Ho KK. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 1995; 80: 1783–8

    Article  PubMed  Google Scholar 

  80. Araujo DA, Farias MLF, Andrade ATL. Effects of transdermal and oral estrogen replacement therapy on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus. Climacteric 2002; 5: 286–92

    PubMed  CAS  Google Scholar 

  81. Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998; 128: 705–12

    PubMed  CAS  Google Scholar 

  82. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999; 106: 574–82

    Article  PubMed  CAS  Google Scholar 

  83. Nanda K, Bastian LA, Hasselblad V, et al. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999; 93: 880–8

    Article  PubMed  CAS  Google Scholar 

  84. Smirnoff P, Liel Y, Gnainsky J, et al. The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonie vitamin D receptor. Oncol Res 1999; 11: 255–64

    PubMed  CAS  Google Scholar 

  85. Fiorelli G, Picariello L, Martineti V, et al. Estrogen metabolism in human colorectal cancer cells. J Steroid Biochem Mol Biol 2002; 81: 281–9

    Article  PubMed  CAS  Google Scholar 

  86. Gambacciani M, Genazzani AR. Hormone replacement therapy: the benefits in tailoring the regimen and dose. Maturitas 2001; 40: 195–201

    Article  PubMed  CAS  Google Scholar 

  87. Montgomery Rice V. Hormone replacement therapy: optimising the dose and route of administration. Drugs Aging 2002; 19: 807–18

    Article  PubMed  Google Scholar 

  88. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304–13

    Article  PubMed  CAS  Google Scholar 

  89. Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001; 8: 245–51

    Article  PubMed  CAS  Google Scholar 

  90. The North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003; 10: 113–32

    Article  Google Scholar 

  91. Boerrigter PJ, van de Weijer PH, Baak JP, et al. Endometrial response in estrogen replacement therapy quarterly combined with a progestogen. Maturitas 1996; 24: 63–71

    Article  PubMed  CAS  Google Scholar 

  92. Cerin A, Heldaas K, Moeller B. Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy: the Scandinavian LongCycle Study Group. N Engl J Med 1996; 334: 668–9

    Article  PubMed  CAS  Google Scholar 

  93. Varila E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001; 76: 969–73

    Article  PubMed  CAS  Google Scholar 

  94. Dören M. Hormonal replacement regimens and bleeding. Maturitas 2000; 34 Suppl. 1: S17–23

    Article  PubMed  Google Scholar 

  95. Hill DA, Weiss NS, Beresford SA, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000; 183: 1456–61

    Article  PubMed  CAS  Google Scholar 

  96. Naftolin F, Silver D. Is progestogen supplementation of ERT really necessary? Menopause 2002; 9: 1–2

    Article  PubMed  Google Scholar 

  97. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002; 9: 6–15

    Article  PubMed  Google Scholar 

  98. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–80

    Article  PubMed  CAS  Google Scholar 

  99. Scarabin P-Y, Oger E, Plu-Bureau G, et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428–32

    Article  PubMed  CAS  Google Scholar 

  100. Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 1116–21

    Article  PubMed  CAS  Google Scholar 

  101. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047–59

    Article  Google Scholar 

  102. Scheele F, Burger CW, Kenemans P. Postmenopausal hormone replacement in the woman with a reproductive risk factor for breast cancer. Maturitas 1999; 33: 191–6

    Article  PubMed  CAS  Google Scholar 

  103. Verheul HA, Coelingh-Bennink HJ, Kenemans P, et al. Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies. Maturitas 2000; 36: 1–17

    Article  PubMed  CAS  Google Scholar 

  104. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–27

    Article  CAS  Google Scholar 

  105. Speroff L. The Million Women Study and breast cancer. Maturitas 2003; 46: 1–6

    Article  PubMed  Google Scholar 

  106. Rodriguez C, Patel AV, Calle EE, et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001; 285: 1460–5

    Article  PubMed  CAS  Google Scholar 

  107. Hernandez E. Relationship between postmenopausal hormone replacement therapy and ovarian cancer. JAMA 2001; 285: 3089–90

    Article  PubMed  CAS  Google Scholar 

  108. Simon JA, Hunninghake DB, Agarwal SK, et al. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease: the Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2001; 135: 493–501

    PubMed  CAS  Google Scholar 

  109. Uhler ML, Marks JW, Voigt BJ, et al. Comparison of the impact of transdermal versus oral estrogens on biliary markers of gallstone formation in postmenopausal women. J Clin Endocrinol Metab 1998; 83: 410–4

    Article  PubMed  CAS  Google Scholar 

  110. Hemminki E, Brambilla DJ, McKinlay SM, et al. Use of estrogens among middle-aged Massachusetts women. DICP 1991; 25: 418–23

    PubMed  CAS  Google Scholar 

  111. Topo P, Koster A, Holte A, et al. Trends in the use of climacteric and postclimacteric hormones in Nordic countries. Maturitas 1995; 22: 89–95

    Article  PubMed  CAS  Google Scholar 

  112. Groeneveld FP, Bareman FP, Barentsen R, et al. Duration of hormonal replacement therapy in general practice: a follow-up study. Maturitas 1998; 29: 125–31

    Article  PubMed  CAS  Google Scholar 

  113. Pitkin J. Compliance with estrogen replacement therapy: current issues. Climacteric 2002; 5 Suppl. 2: 12–9

    PubMed  Google Scholar 

  114. Sturdee DW. Current hormone replacement therapy: what are the shortcomings? Advances in delivery. Int J Clin Pract 1999; 53: 468–72

    PubMed  CAS  Google Scholar 

  115. De Ziegler D, Fanchin R. Progesterone and progestins: applications in gynecology. Steroids 2000; 65: 671–9

    Article  PubMed  CAS  Google Scholar 

  116. Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 75: 1065–79

    Article  PubMed  CAS  Google Scholar 

  117. Delmas PD, Confavreux E, Garnero P, et al. A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteoporos Int 2000; 11: 177–87

    Article  PubMed  CAS  Google Scholar 

  118. Lobo RA. Androgens in postmenopausal women: production, possible role, and replacement options. Obstet Gynecol Surv 2001; 56: 361–76

    Article  PubMed  CAS  Google Scholar 

  119. Bachmann G, Bancroft J, Braunstein G, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002; 77: 660–5

    Article  PubMed  Google Scholar 

  120. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 2001; 76: 231–8

    Article  PubMed  CAS  Google Scholar 

  121. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002; 87: 16–23

    Article  PubMed  CAS  Google Scholar 

  122. Huber J, Palacios S, Berglund L, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 2002; 109: 886–93

    Article  PubMed  CAS  Google Scholar 

  123. Davis SR. The effects of tibolone on mood and libido. Menopause 2002; 9: 162–70

    Article  PubMed  Google Scholar 

  124. Kloosterboer HJ, Ederveen AGH. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (progestogen) treatments. J Steroid Biochem Mol Biol 2003; 83: 157–65

    Article  CAS  Google Scholar 

  125. Freedman RR, Woodward S, Sabharwal SC. Alpha 2-adrenergic mechanism in menopausal hot flushes. Obstet Gynecol 1990; 76: 573–8

    PubMed  CAS  Google Scholar 

  126. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356: 2059–63

    Article  PubMed  CAS  Google Scholar 

  127. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20: 1578–83

    Article  PubMed  CAS  Google Scholar 

  128. Van de Weijer P, Barentsen R. Isoflavones from red clover (Promensil®) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas 2002; 42: 187–93

    Article  PubMed  Google Scholar 

  129. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002; 359: 2018–26

    Article  PubMed  CAS  Google Scholar 

  130. Barrett-Connor E. Raloxifene: risks and benefits. Ann N Y Acad Sci 2001; 949: 295–303

    Article  PubMed  CAS  Google Scholar 

  131. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial: multiple outcomes of raloxifene evaluation. JAMA 1999; 281: 2189–97

    Article  PubMed  CAS  Google Scholar 

  132. Barrett-Connor E, Grady D, Sashegyi A, et al., for the MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287: 847–57

    Article  PubMed  CAS  Google Scholar 

  133. Harris ST. Bisphosphonates for the treatment of postmenopausal osteoporosis: clinical studies of etidronate and alendronate. Osteoporos Int 2001; 12 Suppl. 3: S11–6

    Article  PubMed  CAS  Google Scholar 

  134. Cobin RH. AACE medical guidelines for clinical practice for management of menopause. Endocr Pract 1999; 5: 354–66

    Google Scholar 

  135. National Institutes of Health (NIH). Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 17: 1. Bethesda (MD): NIH, 2000: 1–45

    Google Scholar 

  136. Hodgson SF, Watts NB, Bilezikian JP, et al., for the American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis. Endocr Pract 2001; 7: 293–312

    Google Scholar 

  137. Mosca L, Collins P, Herrington DM, et al., for the American Heart Association. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104: 499–503

    Article  PubMed  CAS  Google Scholar 

  138. Rymer J, Wilson R, Ballard K. Making decisions about hormone replacement therapy. BMJ 2003; 326: 322–6

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Project Aging Women, Institute for Cardiovascular Research - Vrije Universiteit, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands

    Marius Jan van der Mooren & Peter Kenemans

Authors
  1. Marius Jan van der Mooren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Kenemans
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marius Jan van der Mooren.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van der Mooren, M.J., Kenemans, P. Postmenopausal Hormone Therapy. Drugs 64, 821–836 (2004). https://doi.org/10.2165/00003495-200464080-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464080-00003

Keywords

Search

Navigation